Status:

WITHDRAWN

Hair Transplantation for Treatment of Vitiligo

Lead Sponsor:

Mehdi Rashighi

Conditions:

Vitiligo

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

There are several surgical methods to treat vitiligo patches, and follicular unit extraction (FUE) is one among them. FUE, performed using punch biopsy extraction and hair follicle transplantation, ha...

Detailed Description

Vitiligo is an autoimmune skin condition that can have a profound psychosocial impact on patients. Vitiligo is caused by an immune-mediated destruction of melanocytes, or the cells responsible for pro...

Eligibility Criteria

Inclusion

  • Adults 18 years and older
  • Vitiligo patients already on treatment who demonstrate stable disease (have noted some repigmentation in hair bearing areas)
  • Willingness to participate in the study
  • Willingness to undergo biopsies of full-thickness skin tissue from areas without vitiligo and having them transplanted into areas with vitiligo
  • Informed consent agreement signed by the subject

Exclusion

  • Adults unable to consent (adults lacking capacity)
  • Individuals who are not yet adults (infants, children, teenagers)
  • Pregnant women
  • Prisoners
  • Unable to return for follow-up visits
  • Infection or other dermatologic condition different than vitiligo in the area to be treated
  • Personal or family history of keloid formation
  • Known allergies to injectable lidocaine or other topical anesthetics
  • Systemic immunosuppressive medication (oral corticosteroids) within prior 4 weeks
  • Topical steroids at planned recipient site within the prior 1 week
  • Individuals who are unwilling to discontinue topical steroids at recipient site
  • Prescription or over-the-counter medication or cosmetics containing: retinoids, glycolic acid, salicylic acid, topical steroids at the site of treatment or oral corticosteroids, or any other remedies that might affect the healing process. Non-medicated moisturizers are allowed.
  • Co-existent inflammatory skin disease
  • Any other condition or laboratory value that would, in the professional opinion of the investigators, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

Key Trial Info

Start Date :

August 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 15 2023

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04858152

Start Date

August 1 2021

End Date

August 15 2023

Last Update

May 24 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Massachusetts Medical School

Worcester, Massachusetts, United States, 01605